Scottish Medicines Consortium Accepts ABRAXANE[R] for Use within National Health Service for Scotland.

Abraxis BioScience, Inc. (NASDAQ: ABII), a fully integrated biotechnology company, welcomes the announcement today that following a full submission, the Scottish Medicines Consortium (SMC) has accepted ABRAXANE[R] (paclitaxel albumin) for restricted use within the National Health Service (NHS) for Scotland in patients who would otherwise receive docetaxel or 3-weekly solvent-based paclitaxel as second-line treatment for metastatic breast cancer.

"ABRAXANE's acceptance by the SMC is a significant milestone in our goal to provide patients in the United Kingdom and across Europe with an innovative treatment option," said Jean-Francois Gimonet, M.D., Vice President, European …